Good Steward Wealth Advisors LLC Has $374,000 Position in Pfizer Inc. $PFE

Good Steward Wealth Advisors LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 31.5% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 15,429 shares of the biopharmaceutical company’s stock after selling 7,086 shares during the quarter. Good Steward Wealth Advisors LLC’s holdings in Pfizer were worth $374,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Gould Capital LLC raised its holdings in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. bought a new stake in Pfizer during the first quarter worth about $27,000. North Capital Inc. bought a new stake in Pfizer during the first quarter worth about $28,000. Bayforest Capital Ltd bought a new stake in Pfizer during the first quarter worth about $28,000. Finally, Bernard Wealth Management Corp. bought a new stake in Pfizer during the fourth quarter worth about $30,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $23.91 on Friday. The stock has a market cap of $135.94 billion, a P/E ratio of 12.72, a PEG ratio of 0.88 and a beta of 0.55. The stock has a 50 day simple moving average of $24.79 and a 200 day simple moving average of $24.28. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period last year, the firm posted $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 7.2%. The ex-dividend date of this dividend was Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is presently 91.49%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on PFE shares. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. HSBC cut their price objective on Pfizer from $27.00 to $26.00 and set a “buy” rating for the company in a research report on Monday, May 19th. Berenberg Bank cut their price objective on Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. Jefferies Financial Group raised their price objective on Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research report on Wednesday, May 21st. Finally, Morgan Stanley raised their price objective on Pfizer from $32.00 to $33.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.